FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Ascendis NDA for Hypoparathyroidism Therapy

Ascendis Pharma files an NDA for TransCon PTH, an investigational prodrug designed to restore parathyroid hormone (PTH [1-34]) to physiological levels...

latest-news-card-1
Biologics

FDA Authorizes Moderna, Pfizer-BioNTech Boosters

FDA authorizes Modernas and Pfizer-BioNTechs updated (bivalent) Covid-19 vaccines for use as a single booster dose at least two months following prima...

latest-news-card-1
Biologics

FDA Loses California Stem Cell Treatment Case

A California federal judge rejects FDA regulation of a stem cell clinic, saying it is engaged in the practice of medicine.

latest-news-card-1
Medical Devices

Novo Nordisk Pays $6.3 Million Over False Claims

Novo Nordisk agrees to pay $6.3 million to resolve allegations that it violated the False Claims Act by selling its NovoFine needles to U.S. governmen...

latest-news-card-1
Human Drugs

FDA OKs Genzymes Xenpozyme for ASMD

FDA approves Genzymes Xenpozyme to treat acid sphingomyelinase deficiency in children and adults.

latest-news-card-1
Human Drugs

Changes Sought in Drug Shortage Draft Guidance

Two major drug trade associations ask for changes in an FDA draft guidance on risk management plans to mitigate drug shortages.

latest-news-card-1
Medical Devices

Baxter New Novum IQ Syringe Pump Cleared

FDA clears a Baxter International 510(k) clearance of its new Novum IQ syringe infusion pump with Dose IQ Safety Software.

latest-news-card-1
Human Drugs

Amneal Files NDA for Parkinsons Drug

Amneal Pharmaceuticals files an NDA for IPX203, a novel formulation of carbidopa/levodopa extended-release capsules for treating Parkinsons disease.

latest-news-card-1
Federal Register

Ubrelvy Regulatory Review Period Determined

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Allergans Ubrelvy (ubrogepant), indicated for t...

latest-news-card-1
Federal Register

Regulatory Review Period for TherOx Downstream System

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for TherOxs PMA for the TherOx Downstream System, i...